Shuangling Luo

Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial

Huabin Hu, Liang Kang, Jianwei Zhang et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 278 citations

Neoadjuvant Pd-1 Blockade, Medicine, Immunology +7

A highly potent ruthenium(II)-sonosensitizer and sonocatalyst for in vivo sonotherapy

Chao Liang, Jiaen Xie, Shuangling Luo et al. · Nature Communications · 2021 · 156 citations · Full text

A study on coevolutionary dynamics of knowledge diffusion and social network structure

Shuangling Luo, Yanyan Du, Peng Liu et al. · Expert Systems with Applications · 2014 · 76 citations

Network Evolution, Network Science, Social Network Structure +11

A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption

Yidan Lai, Nong Lu, Shuangling Luo et al. · Journal of Medicinal Chemistry · 2022 · 76 citations

Chemoprevention Strategy, Sorafenib Resistance, Redox Biology +20

Morbidity, Mortality, and Pathologic Outcomes of Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer Short-term Outcomes From a Multicenter Randomized Controlled Trial

Huashan Liu, Ziwei Zeng, Hong Zhang et al. · Annals of Surgery · 2022 · 71 citations · Full text